Study #2014-0431
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients with AML and MDS
MD Anderson Study Status
Not Accepting
Treatment Agent
Busulfan, Cladribine, Fludarabine Phosphate, Venetoclax
Description
This randomized phase II trial studies how well venetoclax and sequential busulfan, cladribine, and fludarabine phosphate before donor stem cell transplant work in treating patients with acute myelogenous leukemia or myelodysplastic syndrome. Giving chemotherapy before a donor peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets and may help destroy any remaining cancer cells.
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study phase:
II
Physician name:
Uday Popat
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.